HUE030171T2 - Bicyclo (3.1.0) hexane-2,6-dicarboxylic acid derivatives such as mGlu2 receptor agonists - Google Patents
Bicyclo (3.1.0) hexane-2,6-dicarboxylic acid derivatives such as mGlu2 receptor agonists Download PDFInfo
- Publication number
- HUE030171T2 HUE030171T2 HUE12729769A HUE12729769A HUE030171T2 HU E030171 T2 HUE030171 T2 HU E030171T2 HU E12729769 A HUE12729769 A HU E12729769A HU E12729769 A HUE12729769 A HU E12729769A HU E030171 T2 HUE030171 T2 HU E030171T2
- Authority
- HU
- Hungary
- Prior art keywords
- hydrogen
- compound
- pharmaceutically acceptable
- ahol ahol
- hexane
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382208 | 2011-06-17 | ||
| US201161522791P | 2011-08-12 | 2011-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE030171T2 true HUE030171T2 (en) | 2017-05-29 |
Family
ID=47357416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12729769A HUE030171T2 (en) | 2011-06-17 | 2012-06-07 | Bicyclo (3.1.0) hexane-2,6-dicarboxylic acid derivatives such as mGlu2 receptor agonists |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9296710B2 (enExample) |
| EP (1) | EP2721012B1 (enExample) |
| JP (1) | JP5945592B2 (enExample) |
| KR (1) | KR101598679B1 (enExample) |
| CN (1) | CN103596933B (enExample) |
| AU (1) | AU2012271024B2 (enExample) |
| BR (1) | BR112013031928B1 (enExample) |
| CA (1) | CA2836485C (enExample) |
| CY (1) | CY1117682T1 (enExample) |
| DK (1) | DK2721012T3 (enExample) |
| EA (1) | EA023553B1 (enExample) |
| ES (1) | ES2587204T3 (enExample) |
| HR (1) | HRP20160676T1 (enExample) |
| HU (1) | HUE030171T2 (enExample) |
| MX (1) | MX2013014802A (enExample) |
| PL (1) | PL2721012T3 (enExample) |
| PT (1) | PT2721012T (enExample) |
| RS (1) | RS54888B1 (enExample) |
| SI (1) | SI2721012T1 (enExample) |
| WO (1) | WO2012173850A1 (enExample) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993006127A1 (en) | 1991-09-17 | 1993-04-01 | Warner-Lambert Company | Novel amino acid prodrug renin inhibitors |
| US5576323A (en) | 1993-12-03 | 1996-11-19 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| US5849525A (en) | 1994-03-09 | 1998-12-15 | Brigham And Women's Hospital, Inc. | Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same |
| EA001617B1 (ru) | 1995-11-16 | 2001-06-25 | Эли Лилли Энд Компани | Антагонисты рецепторов возбудительной аминокислоты |
| US5688826A (en) | 1995-11-16 | 1997-11-18 | Eli Lilly And Company | Excitatory amino acid derivatives |
| GB9605429D0 (en) * | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
| US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| ZA983930B (en) | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
| ES2191412T3 (es) | 1998-01-28 | 2003-09-01 | Taisho Pharmaceutical Co Ltd | Derivados de aminoacidos que contienen fluor. |
| DK1110943T3 (da) | 1998-08-31 | 2004-10-11 | Taisho Pharmaceutical Co Ltd | 6-fluorbicyclo[3.1.0]hexanderivater |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| AU6785401A (en) | 2000-06-28 | 2002-01-08 | Taisho Pharmaceutical Co Ltd | Novel dicarboxylic acid derivatives |
| HUP0400620A3 (en) | 2001-01-11 | 2012-09-28 | Lilly Co Eli | Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds |
| WO2002055485A1 (en) | 2001-01-11 | 2002-07-18 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| EP1370519A1 (en) * | 2001-02-22 | 2003-12-17 | Eli Lilly And Company | Synthetic excitatory amino acids |
| WO2002100399A1 (en) | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| ATE405289T1 (de) | 2001-12-27 | 2008-09-15 | Taisho Pharmaceutical Co Ltd | 6-fluorobicyclo 3.1.0 hexan-derivate |
| US20050192273A1 (en) | 2002-04-03 | 2005-09-01 | Johnson Bryan G. | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
| CA2478227A1 (en) | 2002-04-03 | 2003-10-16 | Eli Lilly And Company | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
| CN100482680C (zh) * | 2002-06-11 | 2009-04-29 | 伊莱利利公司 | 兴奋性氨基酸前药 |
| DK1517915T3 (da) | 2002-06-11 | 2009-03-16 | Lilly Co Eli | Promedikamenter af excitatoriske aminosyrer |
| WO2005000790A1 (ja) * | 2003-06-26 | 2005-01-06 | Taisho Pharmaceutical Co., Ltd. | ２－アミノビシクロ[３．１．０]ヘキサン－２，６－ジカルボン酸誘導体 |
| ES2355144T3 (es) * | 2003-06-26 | 2011-03-23 | Taisho Pharmaceutical Co., Ltd. | Derivado de éster 2-aminobiciclo 3.1.0 hexano-2,6-dicarboxílico. |
| CN102741239B (zh) * | 2009-11-18 | 2015-06-24 | 苏文生命科学有限公司 | 作为α4β2烟碱型乙酰胆碱受体配体的双环化合物 |
| JO2978B1 (en) * | 2009-12-21 | 2016-03-15 | ايلي ليلي اند كومباني | MGLU2 aids |
-
2012
- 2012-06-07 BR BR112013031928-3A patent/BR112013031928B1/pt active IP Right Grant
- 2012-06-07 CA CA2836485A patent/CA2836485C/en active Active
- 2012-06-07 AU AU2012271024A patent/AU2012271024B2/en active Active
- 2012-06-07 KR KR1020137033028A patent/KR101598679B1/ko active Active
- 2012-06-07 US US14/123,768 patent/US9296710B2/en active Active
- 2012-06-07 ES ES12729769.5T patent/ES2587204T3/es active Active
- 2012-06-07 MX MX2013014802A patent/MX2013014802A/es active IP Right Grant
- 2012-06-07 SI SI201230569A patent/SI2721012T1/sl unknown
- 2012-06-07 CN CN201280029080.2A patent/CN103596933B/zh active Active
- 2012-06-07 EP EP12729769.5A patent/EP2721012B1/en active Active
- 2012-06-07 JP JP2014515878A patent/JP5945592B2/ja active Active
- 2012-06-07 WO PCT/US2012/041229 patent/WO2012173850A1/en not_active Ceased
- 2012-06-07 PL PL12729769T patent/PL2721012T3/pl unknown
- 2012-06-07 HR HRP20160676TT patent/HRP20160676T1/hr unknown
- 2012-06-07 EA EA201391700A patent/EA023553B1/ru not_active IP Right Cessation
- 2012-06-07 PT PT127297695T patent/PT2721012T/pt unknown
- 2012-06-07 HU HUE12729769A patent/HUE030171T2/en unknown
- 2012-06-07 DK DK12729769.5T patent/DK2721012T3/en active
- 2012-06-07 RS RS20160491A patent/RS54888B1/sr unknown
-
2016
- 2016-06-24 CY CY20161100570T patent/CY1117682T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1117682T1 (el) | 2017-05-17 |
| PT2721012T (pt) | 2016-07-27 |
| SI2721012T1 (sl) | 2016-08-31 |
| EA023553B1 (ru) | 2016-06-30 |
| HRP20160676T1 (hr) | 2016-07-15 |
| US20140113944A1 (en) | 2014-04-24 |
| MX2013014802A (es) | 2014-01-24 |
| CN103596933B (zh) | 2016-03-23 |
| KR20140009568A (ko) | 2014-01-22 |
| EA201391700A1 (ru) | 2014-04-30 |
| DK2721012T3 (en) | 2016-08-15 |
| CA2836485A1 (en) | 2012-12-20 |
| EP2721012B1 (en) | 2016-05-25 |
| EP2721012A1 (en) | 2014-04-23 |
| ES2587204T3 (es) | 2016-10-21 |
| JP2014517035A (ja) | 2014-07-17 |
| CA2836485C (en) | 2016-12-13 |
| CN103596933A (zh) | 2014-02-19 |
| PL2721012T3 (pl) | 2017-05-31 |
| JP5945592B2 (ja) | 2016-07-05 |
| BR112013031928B1 (pt) | 2022-05-24 |
| RS54888B1 (sr) | 2016-10-31 |
| AU2012271024A1 (en) | 2013-11-21 |
| KR101598679B1 (ko) | 2016-02-29 |
| AU2012271024B2 (en) | 2015-07-09 |
| BR112013031928A2 (pt) | 2016-12-13 |
| WO2012173850A1 (en) | 2012-12-20 |
| US9296710B2 (en) | 2016-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2784667C (en) | Mglu2 agonists | |
| AU2018204692A1 (en) | Glutaminase inhibitors and methods of use | |
| EP3330254A2 (en) | Method and process for preparation and production of deuterated omega-diphenylurea | |
| DK2721012T3 (en) | Biclo (3.1.0) hexane-2,6-dicarboxylic acid derivatives as MGLU2 receptor agonist | |
| JP2014517035A5 (enExample) | ||
| HK1171228B (en) | Mglu2 agonists | |
| HUE028863T2 (en) | mGlu 2/3 agonists |